NEWARK, Calif., Sept. 23, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that its president and CEO, Martin McGlynn, is featured on the financial website www.wallstreetreporter.com. In an interview, Mr. McGlynn discussed the Company's recent dosing of the first patient in the Company's Phase I/II clinical trial in chronic spinal cord injury, the Company's efforts to develop its proprietary HuCNS-SC® cells for a range of central nervous system disorders, its other business activities, and its management team. Mr. McGlynn's interview can be accessed online at http://www.wallstreetreporter.com/2011/09/stemcells-inc-nasdaqstem-ceo-interview/.